Abstract
Breast cancer is the leading cause of female cancer deaths. Bone is the commonest site of breast cancer metastasis (40%) will be in the bone. Bone Morphogenetic Protein (BMP) antagonists have been shown to stimulate glycolysis as well as epithelial mesenchymal transition (EMT), which increases the motility of malignant cells and contributes to the development of metastases. The role of GREM1 in HER2+ breast cancer progression remains an under-researched yet promising area of study.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
